FMC FMC
- Market cap
- $1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.4×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.8B
- −22% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- 36.6%
FMC trades at 0.4× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.8B over the last twelve months, down 22% on a year earlier.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.1B−29% | $918M−32% | $1B+2% | $1.1B+9% | $1.2B+7% | $791.4M−14% | $1.1B+1% | $542.2M−49% | $1.1B−12% | $758.6M−4% | $867.1M−18% | $105.9M−81% | |
| Cost of revenue | $710.4M−24% | $578.3M−24% | $640.3M+10% | $679M+13% | $699.6M−2% | $474.7M−18% | $644.2M+1% | $413.3M−39% | $652.2M−7% | $512M+8% | $525M−19% | $507.5M+23% |
| Gross profit | $435.7M−36% | $339.7M−42% | $398.1M−8% | $386.4M+1% | $524.7M+20% | $316.7M−7% | $406.3M+2% | $128.9M−67% | $431.1M−18% | $246.6M−22% | $342.1M−16% | −$401.6M |
| R&D | $81.8M−3% | $60.9M−22% | $75.9M−14% | $69M−15% | $72.2M−12% | $68.7M+13% | $66.4M−13% | $63.3M−8% | $67.7M−6% | $65.5M−5% | $60.4M−9% | $57.7M−9% |
| SG&A | $171.5M−19% | $163.9M−12% | $164.8M−20% | $159.2M−7% | $156.7M−9% | $172M+5% | $176.8M+7% | $167.4M+5% | $168.7M+8% | $185.1M+8% | $179.1M+1% | $172.3M+3% |
| $18.1M−95% | $74M−76% | $62.3M−53% | $135.6M+35% | $234.6M+1196% | $58.2M−21% | $126.4M+103% | −$396.3M | −$1.4B | −$81M | −$119.7M | −$1.1B+181% | |
| Interest expense | $56.7M | $61.7M | $63.6M−1% | $58.7M−9% | $51.8M−9% | $50.1M−19% | $61M−4% | $64.1M+9% | $64.4M+24% | $64.8M+29% | $71.3M+17% | $73.6M+15% |
| Pre-tax income | −$43.4M | $8M−97% | −$5.5M | $72.5M+127% | $177.5M | $4.9M−39% | $58.8M | −$466M | −$1.5B | −$149.2M | −$194.3M | −$1.2B+155% |
| −$1.2B | −$1.4M | −$303.5M | $6M−78% | $148M | $13.5M | $14.4M | $82.2M+1270% | $204.1M+38% | $112.1M+730% | −$1.5M | $840.6M+923% | |
| Net income | $1.1B+301% | −$2.7M | $295.1M+868% | $65M | −$16.3M | −$15.5M+474% | $66.7M−77% | −$569.3M | −$1.7B+10457% | −$281.3M+1715% | −$186.6M | −$2.1B+263% |
| $8.77+304% | −$0.02 | $2.35+879% | $0.52 | −$0.13 | −$0.12+500% | $0.53−77% | −$4.52 | −$13.74+10469% | −$2.25+1775% | −$1.49 | −$15.54+244% | |
| 125.2M−1% | 125.2M−1% | 125.4M−0% | 125.5M+0% | 125.5M+0% | 125.1M−0% | 125.6M+0% | 125.2M−0% | 125.2M−0% | 125.3M+0% | 125.4M−0% | 133M+6% |
Gross profit: 12 periods, Q2 FY08 to Q1 FY11: not printed by the filing, worked out from its own lines.
EPS, diluted: Q4 FY09 and Q4 FY10: quarter's net income to common over its shares, to the cent, the shares from counts implied by EPS, near the year's EPS less the nine months'.
Diluted shares: Q1 FY09 and Q2 FY09: not printed by the filing, worked out from its own lines.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Chemicals nearest FMC's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| FMCFMC | $1B | n/m | 23.3× | 0.4× | −22% | n/m | |
| FTKFlotek Industries | $850.1M | 23.7× | 27.5× | 2.9× | +37% | 13.0% | |
| CRONCronos | $1.2B | 16.6× | 24.9× | 6.9× | +37% | 39.1% | |
| ROGRogers | $2.3B | 50.7× | 34.4× | 2.7× | +7% | 5.3% | |
| IOSPInnospec | $2.5B | 20.3× | 22.3× | 1.3× | +3% | 6.6% | |
| NGVTIngevity | $2.5B | 50.1× | 20.1× | 2.2× | −4% | 4.7% | |
| FULFuller H B | $2.8B | 14.4× | 22.8× | 0.8× | +1% | 5.6% | |
| WDFCWD 40 | $3.1B | 37.5× | 39.2× | 4.4× | +11% | 12.0% | |
| CBTCabot | $3.9B | 21.4× | 14.4× | 1.1× | −5% | 5.2% | |
| AVNTAvient | $4B | 23.5× | 20.3× | 1.2× | +2% | 5.1% | |
| CSWCSW Industrials | $4.7B | 36.9× | 34.8× | 3.7× | +30% | 10.2% | |
| Peer median | $2.7B | 23.6× | 23.8× | 2.4× | +5% | 6.1% |
More on FMC
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #1of 88Materials stocks with the highest free cash flow yield
- #1of 26Chemicals stocks with the highest free cash flow yield
Its groups
About
- Industry
- Chemicals
- Sector
- Basic Materials
Valuation data, not investment advice. Prices as of .